NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDCR E-257-2012-0-US-03 Methods of Preventing the Development of Mucositis and Related Disorders US CON 15/063,256 Abandoned
NCI E-340-2007-0-US-15 Methods and Compositions for Increasing the Efficacy of Doxorubic in Treatment in the Treatment of Prostate Related Disorders using miR-106b-25 Cluster US DIV 15/062,414 Abandoned
NCI E-340-2007-0-US-14 Methods and Compositions for the Treatment of Prostate Related Disorders using miR-32 US DIV 15/062,411 Abandoned
NCI E-340-2007-0-US-13 Methods and Compositions for the Treatment of Prostate Related Disorders using miR-106b US DIV 15/062,407 Abandoned
NIDCD E-043-2016-0-US-01 MICRORNAS AND METHODS OF THEIR USE US 62/304,844 Abandoned
NHGRI E-282-2012-2-US-01 Cannabinoid Receptor Mediating Compounds US CIP 15/061,829 11155521 Issued PDF
NCI E-034-2010-0-CA-04 .BETA.-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY CA National Stage 2792754 Issued
NCI E-281-2016-0-PCT-02 Quinolinones As Inhibitors Of Translation Initiation Complex PCT PCT PCT/US2016/020273 Expired
NCI E-290-2006-2-US-34 Methods of Inhibiting Tumorigenesis in Colon Adenocarcinoma and Compositions Therefor US DIV 15/057,308 Abandoned
NCI E-166-2007-0-US-07 FILIP1L Nucleic Acid Fragments US DIV 15/058,116 Abandoned
CC E-045-2016-0-US-01 Recurrent Neural Feedback Model For Automated Image Annotation US 62/302,084 Abandoned
CC E-046-2016-0-US-01 Category Discovery And Image Auto-Annotation Via Looped Deep Pseudo-Task Optimization US 62/302,096 Abandoned
NIAID E-242-2014-0-US-03 Anti-Malarial Compositions US DIV 15/056,458 1016-08-02 Issued PDF
NCATS E-072-2015-0-CO-09 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMA CO National Stage 16051864 Issued
NCATS E-072-2015-0-US-15 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMIA US National Stage 14/915,602 9952199 Issued PDF
NHLBI E-249-2006-3-US-01 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection Device US CIP 15/056,599 9943409 Abandoned PDF
NCATS E-072-2015-0-CL-07 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMA CL National Stage 2016000467 Pending
NIAID E-106-2016-0-US-01 PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE US 62/300,822 Abandoned
NCATS E-072-2015-0-JP-12 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMA JP National Stage 2016-537941 Issued
NIAID E-219-2016-0-US-04 Serum Antibody Assay For Determining Protection From Malaria, And Pre-Erythrocytic Subunit Vaccines US National Stage 14/914,869 Abandoned
NCATS E-072-2015-0-IL-11 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMA IL National Stage 244274 Issued
NIAID E-239-2014-0-PCT-02 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE PCT PCT PCT/US2016/019395 Expired
NIAID E-239-2014-0-EP-03 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE EP National Stage 16711059.2 Abandoned
NIAID E-052-2017-1-EP-01 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection EP ORD 16305211.1 Pending
NCI E-105-2016-0-US-01 Methods of Producing T Cell Populations Using Hyperkalemic Cell Culture Medium US 62/299,095 Abandoned
NEI E-113-2010-0-CA-04 Nitisinone For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation CA National Stage 2791245 Issued
NCI E-116-2001-0-CY-63 Formulation of Boronic Acid Compounds CY EP 16157001.5 Expired
NCI E-116-2001-0-AT-60 Formulation of Boronic Acid Compounds AT EP 16157001.5 Expired
NCI E-116-2001-0-BE-61 Formulation of Boronic Acid Compounds BE EP 16157001.5 Expired
NCI E-116-2001-0-PT-77 Formulation of Boronic Acid Compounds PT EP 16157001.5 Expired
NCI E-116-2001-0-MC-75 Formulation of Boronic Acid Compounds MC EP 16157001.5 Expired
NCI E-116-2001-0-NL-76 Formulation of Boronic Acid Compounds NL EP 16157001.5 Expired
NCI E-116-2001-0-FR-68 Formulation of Boronic Acid Compounds FR EP 16157001.5 Expired
NCI E-116-2001-0-FI-67 Formulation of Boronic Acid Compounds FI EP 16157001.5 Expired
NCI E-116-2001-0-DE-64 Formulation of Boronic Acid Compounds DE EP 16157001.5 Expired
NCI E-116-2001-0-DK-65 Formulation of Boronic Acid Compounds DK EP 16157001.5 Expired
NCI E-116-2001-0-IE-71 Formulation of Boronic Acid Compounds IE EP 16157001.5 Expired
NCI E-116-2001-0-GR-70 Formulation of Boronic Acid Compounds GR EP 16157001.5 Expired
NCI E-116-2001-0-IT-72 Formulation of Boronic Acid Compounds IT EP 16157001.5 Expired
NCI E-116-2001-0-SE-78 Formulation of Boronic Acid Compounds SE EP 16157001.5 Expired
NCI E-116-2001-0-GB-69 Formulation of Boronic Acid Compounds GB EP 16157001.5 Expired
NCI E-116-2001-0-CH-62 Formulation of Boronic Acid Compounds CH EP 16157001.5 Expired
NCI E-116-2001-0-ES-66 Formulation of Boronic Acid Compounds ES EP 16157001.5 Expired
NCI E-116-2001-0-TR-79 Formulation of Boronic Acid Compounds TR EP 16157001.5 Expired
NCI E-116-2001-0-LI-73 Formulation of Boronic Acid Compounds LI EP 16157001.5 Expired
NCI E-116-2001-0-LU-74 Formulation of Boronic Acid Compounds LU EP 16157001.5 Expired
NCI E-116-2001-0-EP-59 Formulation of Boronic Acid Compounds EP DIV 16157001.5 Expired
NHGRI E-092-2014-1-PCT-02 Sialylation-Increasing Therapies For Diseases Associated With Oxidative Stress PCT PCT PCT/US2016/019084 Expired
NHGRI E-007-1999-2-US-10 Cellular Arrays and Methods of Detecting and Using Genetic Disorder Markers US CON 15/051,147 Expired
NHGRI E-092-2014-1-EP-04 Sialylation-Increasing Therapies For Diseases Associated With Oxidative Stress EP National Stage 16714599.4 Abandoned